It has been well established that, in contrast to what has been observed in ER-/HER2+/AR+ tumors, HER2+ BC cases expressing high ER and AR levels have smaller tumor sizes, lower Ki-67 percentages, less aggressive phenotypes, and better outcomes [28,29,57,58]. The gene discussed is AR; the disease is breast cancer.